Dasatinib

目录号：S1021 别名： BMS-354825

Molecular Weight(MW): 488.01

Dasatinib是一种新型有效的多靶点抑制剂，作用于Abl，Src和 c-Kit，在无细胞试验中IC50分别为 <1 nM，0.8 nM 和 79 nM。

规格

价格

库存

购买数量

10mM/1mL In DMSO	RMB 1142.64	现货
25mg	RMB 1224.97	现货
100mg	RMB 3039.93	现货
大包装	有超大折扣

大剂量询单有大折扣！

今日订购，明日送达，全国免运费！

全国免费电话：400-668-6834 | Email：info@selleck.cn

客户使用Selleck该产品发表文献137篇：

Cancer Cell, 2019, 36(2):179-193

PubMed: 31378681 ( click the link to review the publication )

Nature, 2017, 543(7647):728-732

PubMed: 28321130 ( click the link to review the publication )

Nat Med, 2017, 23(12):1424-1435

PubMed: 29131160 ( click the link to review the publication )

Cancer Discov, 2016, 6(7):727-39

PubMed: 27231123 ( click the link to review the publication )

Cell Stem Cell, 2012, 10(2):210-7

PubMed: 22305570 ( click the link to review the publication )

Cancer Discov, 2011, 1(7):608-25

PubMed: 22586683 ( click the link to review the publication )

Cancer Res, 2019, 79(1):209-219

PubMed: 30389701 ( click the link to review the publication )

Haematologica, 2019, 10.3324/haematol.2019.215939

PubMed: 31289206 ( click the link to review the publication )

Theranostics, 2019, 9(7):1952-1964

PubMed: 31037149 ( click the link to review the publication )

Thyroid, 2019, 29(3):395-404

PubMed: 30724135 ( click the link to review the publication )

Stem Cell Reports, 2019, 10.1016/j.stemcr.2019.08.005

PubMed: 31522974 ( click the link to review the publication )

J Physiol, 2019, 597(6):1627-1642

PubMed: 30488437 ( click the link to review the publication )

Mol Biol Cell, 2019, 30(9):1108-1117

PubMed: 30785867 ( click the link to review the publication )

Sci Rep, 2019, 9(1):7617

PubMed: 31110200 ( click the link to review the publication )

BMC Cancer, 2019, 19(1):485

PubMed: 31118072 ( click the link to review the publication )

Int J Parasitol Drugs Drug Resist, 2019, 9:80-86

PubMed: 30771616 ( click the link to review the publication )

PLoS One, 2019, 14(2):e0212210

PubMed: 30779812 ( click the link to review the publication )

Leuk Lymphoma, 2019, 60(1):189-199

PubMed: 29741440 ( click the link to review the publication )

Environ Mol Mutagen, 2019, 60(6):513-533

PubMed: 30702769 ( click the link to review the publication )

Leuk Res, 2019, 78:12-20

PubMed: 30660961 ( click the link to review the publication )

J Immunol Methods, 2019, 464:22-30

PubMed: 30347189 ( click the link to review the publication )

J Hematol Oncol, 2018, 11(1):85

PubMed: 29925404 ( click the link to review the publication )

Cell Mol Life Sci, 2018, 75(22):4223-4234

PubMed: 29955905 ( click the link to review the publication )

J Exp Clin Cancer Res, 2018, 37(1):183

PubMed: 30081903 ( click the link to review the publication )
Cell Commun Signal, 2018, 16(1):21

PubMed: 29776413 ( click the link to review the publication )

Mol Cancer Res, 2018, 16(10):1556-1567

PubMed: 29903769 ( click the link to review the publication )

Food Chem Toxicol, 2018, 119:464-478

PubMed: 29097117 ( click the link to review the publication )

J Proteome Res, 2018, 17(1):63-75

PubMed: 29164889 ( click the link to review the publication )

Front Pharmacol, 2018, 9:1285

PubMed: 30473665 ( click the link to review the publication )

Int J Oncol, 2018, 52(6):2061-2068

PubMed: 29620253 ( click the link to review the publication )

Cytokine, 2018, 111:209-215

PubMed: 30176559 ( click the link to review the publication )

Toxicol Lett, 2018, 296:39-47

PubMed: 30086328 ( click the link to review the publication )

Transl Oncol, 2018, 11(6):1406-1418

PubMed: 30219696 ( click the link to review the publication )

FEBS Open Bio, 2018, 8(5):732-742

PubMed: 29744288 ( click the link to review the publication )

Nature, 2018, 563(7730):265-269

PubMed: 30401838 ( click the link to review the publication )

Sci Transl Med, 2017, 9(414)10

PubMed: 29093181 ( click the link to review the publication )

Blood, 2017, 129(11):e26-e37

PubMed: 28122742 ( click the link to review the publication )

Clin Cancer Res, 2017, 23(23):7360-7374

PubMed: 28939749 ( click the link to review the publication )

Elife, 2017, 10.7554/eLife.25946

PubMed: 28598329 ( click the link to review the publication )

J Hematol Oncol, 2017, 10(1):118

PubMed: 28606127 ( click the link to review the publication )

Mol Cancer Ther, 2017, 16(11):2387-2398

PubMed: 28775147 ( click the link to review the publication )

Mol Cancer Ther, 2017, 16(9):1729-1738

PubMed: 28619758 ( click the link to review the publication )

Neoplasia, 2017, 19(4):354-363

PubMed: 28319809 ( click the link to review the publication )

Toxicol Sci, 2017, 162(1):146-166

PubMed: 29106658 ( click the link to review the publication )

Cancer Med, 2017, 6(4):809-818

PubMed: 28316141 ( click the link to review the publication )

Clin Res Hepatol Gastroenterol, 2017, 41(6):677-686

PubMed: 28578938 ( click the link to review the publication )

Onco Targets Ther, 2017, 10:73-83

PubMed: 28123301 ( click the link to review the publication )

Eur J Haematol, 2017, 99(5):442-448

PubMed: 28881484 ( click the link to review the publication )
Arch Pharm Res, 2017, 40(2):197-203

PubMed: 27988882 ( click the link to review the publication )

Mol Vis, 2017, 23:823-831

PubMed: 29225458 ( click the link to review the publication )

Ther Drug Monit, 2017, 39(3):252-262

PubMed: 28490048 ( click the link to review the publication )

Leukemia, 2016, 30(6):1273-81

PubMed: 26987906 ( click the link to review the publication )

Leukemia, 2016, 30(7):1493-501

PubMed: 27044711 ( click the link to review the publication )

Cancer Res, 2016, 76(12):3520-30

PubMed: 27197167 ( click the link to review the publication )

Int J Cancer, 2016, 139(10):2359-69

PubMed: 27434411 ( click the link to review the publication )

Cancer Lett, 2016, 376(1):188-96

PubMed: 26996299 ( click the link to review the publication )

Breast Cancer Res, 2016, 18(1):80

PubMed: 27495374 ( click the link to review the publication )

J Infect Dis, 2016, 213(11):1767-76

PubMed: 26802142 ( click the link to review the publication )

Stem Cells Int, 2016, 2016:9601493

PubMed: 26788073 ( click the link to review the publication )

BMC Cancer, 2016, 16:229

PubMed: 26984511 ( click the link to review the publication )

Oncol Lett, 2016, 12(5):3598-3608

PubMed: 27900042 ( click the link to review the publication )

Assay Drug Dev Technol, 2016, 14(7):395-406

PubMed: 27552144 ( click the link to review the publication )

Sci Transl Med, 2015, 7(284):284ra57

PubMed: 25904741 ( click the link to review the publication )

Blood, 2015, 125(8):1282-91

PubMed: 25515960 ( click the link to review the publication )

Leukemia, 2015, 29(3):586-597

PubMed: 25134459 ( click the link to review the publication )

Cancer Lett, 2015, 10.1016/j.canlet.2015.02.044

PubMed: 25737303 ( click the link to review the publication )

Cell Death Dis, 2015, 6:e1767

PubMed: 25996294 ( click the link to review the publication )

Radiother Oncol, 2015, 116(3):431-7

PubMed: 26320552 ( click the link to review the publication )

ACS Chem Biol, 2015, 10(1):262-8

PubMed: ( click the link to review the publication )

Eur Neuropsychopharmacol, 2015, 25(8):1275-86

PubMed: 25983018 ( click the link to review the publication )

J Cell Sci, 2015, 128(2):251-65

PubMed: ( click the link to review the publication )

Eur Neuropsychopharm, 2015, 10.1016/j.euroneuro.2015.04.021

PubMed: ( click the link to review the publication )
Clin Immunol, 2015, 157(2):205-215

PubMed: 25728491 ( click the link to review the publication )

Neurotox Res, 2015, 27(4):384-98

PubMed: 25782580 ( click the link to review the publication )

Arch Biochem Biophys, 2015, 10.1016/j.taap.2015.03.018

PubMed: 25843419 ( click the link to review the publication )

PLoS One, 2015, 10(6):e0129663

PubMed: 26061184 ( click the link to review the publication )

Pulm Pharmacol Ther, 2015, 10.1016/j.pupt.2015.03.001

PubMed: 25843005 ( click the link to review the publication )

Leuk Res, 2015, 10.1016/j.leukres.2015.08.007

PubMed: 26346348 ( click the link to review the publication )

Mol Med Rep, 2015, 12(3):3249-3256

PubMed: 25975261 ( click the link to review the publication )

Int J Clin Exp Pathol, 2015, 8(7):7818-24

PubMed: 26339346 ( click the link to review the publication )

Childs Nerv Syst, 2015, 31(2):221-6

PubMed: 25269544 ( click the link to review the publication )

Childs Nerv Syst, 2015, 31(4):557-62

PubMed: 25712742 ( click the link to review the publication )

Childs Nerv Syst, 2015, 31(2):221-6

PubMed: ( click the link to review the publication )

Oncotarget, 2015, 6(14):12405-20

PubMed: 25915159 ( click the link to review the publication )

Blood, 2014, 123(21):3296-304

PubMed: 24723681 ( click the link to review the publication )

Nat Commun, 2014, 5:3384

PubMed: 24594970 ( click the link to review the publication )

Leukemia, 2014, 28(10):2109-12

PubMed: 24919804 ( click the link to review the publication )

Cancer Lett, 2014, 344(1):90-100

PubMed: 24513268 ( click the link to review the publication )

Cell Death Dis, 2014, 5:e1023

PubMed: 24457967 ( click the link to review the publication )

Cell Death Dis, 2014, 6:e1595

PubMed: 25590805 ( click the link to review the publication )

J Cell Sci, 2014, 127(Pt 14):3039-51

PubMed: 24928894 ( click the link to review the publication )

Int J Mol Sci, 2014, 15(4):5838-51

PubMed: 24714091 ( click the link to review the publication )

Exp Cell Res, 2014, 328(1):20-31

PubMed: 25128812 ( click the link to review the publication )

J Pharm Biomed Anal, 2014, 94:125-31

PubMed: 24561338 ( click the link to review the publication )

PLoS One, 2014, 9(1):e85485

PubMed: 24427313 ( click the link to review the publication )

Mol Biosyst, 2014, 10.1039/C4MB00224E

PubMed: 25099472 ( click the link to review the publication )
Biochem Biophys Res Commun, 2014, 455(3-4):256-61

PubMed: 25449280 ( click the link to review the publication )

Leuk Lymphoma, 2014, 10.3109/10428194.2014.898759

PubMed: 24597981 ( click the link to review the publication )

Biochem Biophy Res Co, 2014, 10.1016/j.bbrc.2014.11.002

PubMed: ( click the link to review the publication )

Head Neck, 2014, 36(3):375-84

PubMed: 23729178 ( click the link to review the publication )

Graefes Arch Clin Exp Ophthalmol, 2014, 10.1007/s00417-014-2674-7

PubMed: 24874745 ( click the link to review the publication )

Mol Med Rep, 2014, 10(5):2729-35

PubMed: 25199623 ( click the link to review the publication )

Head Neck, 2014, 10.1002/hed.23822.

PubMed: 24986420 ( click the link to review the publication )

Oncoscience, 2014, 1(1):57-68

PubMed: 25593988 ( click the link to review the publication )

J Exp Med, 2013, 210(11):2205-21

PubMed: 24127489 ( click the link to review the publication )

J Exp Med, 2013, 210(12):2569-82

PubMed: 24190431 ( click the link to review the publication )

Clin Cancer Res, 2013, 19(18):5053-67

PubMed: 23900136 ( click the link to review the publication )

Cancer Lett, 2013, 340(1):43-50

PubMed: 23811285 ( click the link to review the publication )

Neoplasia, 2013, 15(11):1272-81

PubMed: 24339739 ( click the link to review the publication )

J Thorac Cardiovasc Surg, 2013, 145(2):531-8

PubMed: 23142123 ( click the link to review the publication )

J Neurochem, 2013, 12(12):2864-73

PubMed: 24130049 ( click the link to review the publication )

J Biol Chem, 2013, 288(8):5553-61

PubMed: 23303179 ( click the link to review the publication )

Int J Oncol, 2013, 43(6):2064-72

PubMed: 24126464 ( click the link to review the publication )

Cancer Chemother Pharmacol, 2013, 72(1):35-44

PubMed: 23712327 ( click the link to review the publication )

Pharmgenomics Pers Med, 2013, 6:63-72

PubMed: 24019750 ( click the link to review the publication )

Sci Rep, 2013, 3:2100

PubMed: 23812503 ( click the link to review the publication )

Blood, 2012, 119(21):4981-91

PubMed: 22411867 ( click the link to review the publication )

Clin Cancer Res, 2012, 18(1):127-39

PubMed: 22090359 ( click the link to review the publication )

Proc Natl Acad Sci USA, 2012, 109(17):6584-10

PubMed: 22492965 ( click the link to review the publication )

Oncogene, 2012, 32(37):4331-42

PubMed: 23085751 ( click the link to review the publication )
Br J Haematol, 2012, 157(4):510-4

PubMed: 22313359 ( click the link to review the publication )

J Virol, 2012, 86(16):8765-72

PubMed: 22696643 ( click the link to review the publication )

Angiogenesis, 2012, 15(1):33-45

PubMed: 22203239 ( click the link to review the publication )

Cancer Immunol Immun, 2012, 61(2):193-202

PubMed: 21874302 ( click the link to review the publication )

Invest New Drugs, 2012, 30(1):417-22

PubMed: 20953816 ( click the link to review the publication )

Stem Cells Dev, 2012, 21(16):2939-48

PubMed: 22642671 ( click the link to review the publication )

Hematol Oncol, 2012, 31(3):156-63

PubMed: 23108877 ( click the link to review the publication )

PLoS One, 2012, 7(7):e40853

PubMed: 22815843 ( click the link to review the publication )

J Biomol Screen, 2012, 18(4):388-99

PubMed: 23134735 ( click the link to review the publication )

J Liq Chromatogr R T, 2012, 2503-2510

PubMed: ( click the link to review the publication )

Cell Res, 2011, 21(7):1080-7

PubMed: 21423276 ( click the link to review the publication )

J Mol Biol, 2011, 411(2):474-85

PubMed: 21699901 ( click the link to review the publication )

J Virol, 2011, 85(5):2296-303

PubMed: 21177802 ( click the link to review the publication )

Cancer Prev Res , 2011, 4(8):1222-32

PubMed: 21546539 ( click the link to review the publication )

J Biol Chem, 2011, 286(16):13846-51

PubMed: 21343293 ( click the link to review the publication )

Exp Hematol, 2011, 39(8):859-65.e2

PubMed: 21689725 ( click the link to review the publication )

PLoS One, 2010, 5(11):e14143

PubMed: 21152443 ( click the link to review the publication )

产品安全说明书

Src抑制剂选择性比较

生物活性

产品描述

Dasatinib是一种新型有效的多靶点抑制剂，作用于Abl，Src和 c-Kit，在无细胞试验中IC50分别为 <1 nM，0.8 nM 和 79 nM。

靶点

Abl ^[1] (Cell-free assay)	Src ^[1] (Cell-free assay)	c-Kit (D816V) ^[2] (Cell-free assay)	c-Kit (wt) ^[2] (Cell-free assay)
0.6 nM	0.8 nM	37 nM	79 nM

体外研究

在抑制表达野生型Bcr-Abl或全部Bcr-Abl突变型（除了T315I）的Ba/F3增殖时，Dasatinib效果比Imatinib高很多。与Imatinib相比，Dasatinib呈2倍指数增长效力(约325倍)。Dasatinib有效抑制野生型Abl 激酶和全部突变型（除了T315I）。Dasatinib 直接靶向作用于野生型和突变型Abl激酶域，且抑制自磷酸化和底物磷酸化，这种作用存在浓度依赖性。Dasatinib作用于表达野生型 Bcr-Abl的细胞时，效果比Imatinib高325倍多。^[1] TgE骨髓细胞菌落百分数从未处理孔的100% 降低到Dasatinib处理孔的4.12%。有 Dasatinib存在时, WT 和TgE骨髓细胞形成的菌落百分数明显不同。LMP2A的表达可促进 B 淋巴细胞存活和增殖，而Dasatinib通过靶向作用于Lyn 和/或c-Abl 激酶可抑制以上存活和增殖。^[2] Dasatinib 处理一系列甲状腺癌细胞，抑制Src信号, 降低生长速度,使细胞周期停滞，且诱导凋亡。使用剂量不断增加的 Dasatinib (0.019 μM 到 1.25 μM) 处理C643, TPC1, BCPAP, 和 SW1736 细胞3天，抑制50%细胞生长，然而抑制K1细胞系生长则需更高浓度Dasatinib。使用10 nM 或50 nM Dasatinib 处理BCPAP，SW1736 和 K1 细胞，导致G1期细胞提高9-22%，而S期细胞百分数则降低7-18%。^[3]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID
M07ep210	NITWTYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NV;wVGR{PzJiaB?=	NH7DRnhFVVOR	NX72VoZuUUN3ME2wMlAxODB5IN88US=>	NGPtSZcyPzl3NkC4NC=>
K562	MojwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MUi3NkBp	NXnuTmNmTE2VTx?=	NYjF[FJXUUN3ME2wMlAxOSEQvF2=	MkTrNVc6PTZyOEC=
M07e	NYT0XGFxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NXnpOGZ2PzJiaB?=	NWrqdpBPTE2VTx?=	MkDOTWM2OD1yLkCwNVIh\|ryP	M3;GUFE4QTV4MEiw
ALL3	MVHDfZRwfG:6aXOgRZN{[Xl?	NV7QNHhQOC5zzszN	M17n[\|czKGh?	MmCySG1UVw>?	MUXJR\|UxRTBwMECwOEDPxE1?	M4XifVE6QDh7NUSw
CML	NIXjOFRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NVHXPHVwOjBibXnu	M2HSTGROW09?	NW\WW\|k{UUN3ME2wMlAxOSEQvF2=	M3LxWFE6OjF7MEG2
BA/F3	M3;2cWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MYW3NkBp	M2fjfWROW09?	NFn3XYtKSzVyPU[uOVg6KM7:TR?=	M1;4V\|I{ODh6NkS0
BA/F3	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NW\LVZRwPzJiaB?=	MXnEUXNQ	NW\5RZF5UW6mdXPld{BidnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JI1wfXOnIFLBM2Y{KGOnbHzzJIV5eHKnc4PpcochSmO{LVHicEBOOzVzVDDteZRidnRid3n0bEBKSzVyIH;mJFAvODByOEROwG0>	M2DtelI{ODh6NkS0
BA/F3	M1j1PGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NXXVZWk1PzJiaB?=	MoLOSG1UVw>?	MUDJcoR2[2W\|IHHueIlxem:uaX\ldoF1cX[nIHHjeIl3cXS7IHHnZYlve3RibX;1d4UhSkFxRkOgZ4VtdHNiZYjwdoV{e2mwZzD3bYxlKHS7cHWgRoNzNUGkbDD3bZRpKEmFNUCgc4YhOC5yMES1{txO	NGj5NmQzOzB6OE[0OC=>
BA/F3	MmfRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MWO3NkBp	M4X2XGROW09?	MULJcoR2[2W\|IHHueIlxem:uaX\ldoF1cX[nIHHjeIl3cXS7IHHnZYlve3RibX;1d4UhSkFxRkOgZ4VtdHNiZYjwdoV{e2mwZzDCZ5IuSWKuIGSzNVVKKG23dHHueEB4cXSqIFnDOVAhd2ZiMT63NVTPxE1?	MoHENlMxQDh4NES=
BA/F3	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		M1HJ[VczKGh?	M{[xUmROW09?	MYLJcoR2[2W\|IHP5eI91d3irY3n0fUBi\2GrboP0JI1wfXOnIFLBM2Y{KGOnbHzzJIV5eHKnc4PpcochSkOULVHCUEBHPDh4UzDteZRidnRiYYPz[ZN{\WRiYYOg[5Jwf3SqIFnubIljcXSrb36ge4l1cCCLQ{WwJI9nKDBwMECwPe69VQ>?	Ml3kNlM{ODF5MEO=
BA/F3	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NUP6SnNjPzJiaB?=	M{PZXWROW09?	NFLseXBKdmS3Y3XzJIN6fG:2b4jpZ4l1gSCjZ3HpcpN1KG2xdYPlJGJCN0Z\|IHPlcIx{KGW6cILld5NqdmdiQlPSMWFDVCCHMkW1T{BufXSjboSgZZN{\XO\|ZXSgZZMh\3Kxd4ToJGlvcGmkaYTpc44hf2m2aDDJR\|UxKG:oIECuNFA{Os7:TR?=	M2KzcFI{OzBzN{Cz
BA/F3	MkLuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MlzWO\|IhcA>?	NV7ofmp{TE2VTx?=	MVPJcoR2[2W\|IHP5eI91d3irY3n0fUBi\2GrboP0JI1wfXOnIFLBM2Y{KGOnbHzzJIV5eHKnc4PpcochSkOULVHCUEBIOjVyRTDteZRidnRiYYPz[ZN{\WRiYYOg[5Jwf3SqIFnubIljcXSrb36ge4l1cCCLQ{WwJI9nKDBwMEC1Ne69VQ>?	NVu0Uo5lOjN\|MEG3NFM>
BA/F3	NXju[HFET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		M2HJNFczKGh?	M1WwSGROW09?	MV3JcoR2[2W\|IHP5eI91d3irY3n0fUBi\2GrboP0JI1wfXOnIFLBM2Y{KGOnbHzzJIV5eHKnc4PpcochSkOULVHCUEBSOjV{SDDteZRidnRiYYPz[ZN{\WRiYYOg[5Jwf3SqIFnubIljcXSrb36ge4l1cCCLQ{WwJI9nKDBwMEC4{txO	MXuyN\|MxOTdyMx?=
BA/F3	M3KyXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MlvYO\|IhcA>?	MYTEUXNQ	MWnJcoR2[2W\|IHP5eI91d3irY3n0fUBi\2GrboP0JI1wfXOnIFLBM2Y{KGOnbHzzJIV5eHKnc4PpcochSkOULVHCUEBGOzV7VjDteZRidnRiYYPz[ZN{\WRiYYOg[5Jwf3SqIFnubIljcXSrb36ge4l1cCCLQ{WwJI9nKDBwMECxN:69VQ>?	MoHvNlM{ODF5MEO=
BA/F3	NFrnZ4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MlXyO\|IhcA>?	NVizZVVZTE2VTx?=	MXjJcoR2[2W\|IHP5eI91d3irY3n0fUBi\2GrboP0JI1wfXOnIFLBM2Y{KGOnbHzzJIV5eHKnc4Ppcochf2muZDD0fZBmKEKFUj3BRmwh[XO\|ZYPz[YQh[XNiZ4Lve5RpKEmwaHnibZRqd25id3n0bEBKSzVyIH;mJFAvODBzOd88US=>	MmHGNlM{ODF5MEO=
BA/F3	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NH\KVlc4OiCq	NEDJZnlFVVOR	NUHUd4s4UW6mdXPld{BkgXSxdH;4bYNqfHliYXfhbY5{fCCvb4Xz[UBDSS:IMzDj[YxteyCneIDy[ZN{cW6pIFLDVk1CSkxiWUK1N2ghdXW2YX70JIF{e2W\|c3XkJIF{KGe{b4f0bEBKdmirYnn0bY9vKHerdHigTWM2OCCxZjCwMlAxOjQQvF2=	MmfTNlM{ODF5MEO=
BA/F3	M2XFWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MkfyO\|IhcA>?	NWH1WXljTE2VTx?=	MXvJcoR2[2W\|IHP5eI91d3irY3n0fUBi\2GrboP0JI1wfXOnIFLBM2Y{KGOnbHzzJIV5eHKnc4PpcochSkOULVHCUEBVOzF3STDteZRidnRiYYPz[ZN{\WRiYYOg[5Jwf3SqIFnubIljcXSrb36ge4l1cCCLQ{WwJI9nKDNwNt88US=>	M2XPdlI{OzBzN{Cz
BA/F3	MlfVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NH;tVVY4OiCq	M4Hw[WROW09?	NVPwb3RTUW6mdXPld{BkgXSxdH;4bYNqfHliYXfhbY5{fCCvb4Xz[UBDSS:IMzDj[YxteyCjc4Pld5Nm\CCjczDndo94fGhiSX7obYJqfGmxbjD3bZRpKEmFNUCgc4YhOi53zszN	NFrYe2UzOzNyMUewNy=>
T cell	MlLFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MkXjO\|IhcA>?	M3v0U2ROW09?	NHnJU\|lKdmirYnn0d{BidnSrIFPEN{0h[W6mIHHueIkhS0R{OD3pcoR2[2WmIGSgZ4VtdCCycn;sbYZmemG2aX;uJJdqfGhiSVO1NEBw\iByLkCwN:69VQ>?	MWmxO\|E2PDVzMh?=
WiDr	NUSx[pVLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MoTuO\|IhcA>?	NYqzcXZ7TE2VTx?=	M2H5NGlEPTB;MD6wOVIh\|ryP	MVmxOVYyPTVzMh?=
PC3	MljyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NV3vZZB3PzJiaB?=	NV21O4tWTE2VTx?=	MYXJR\|UxRTBwMEC5OEDPxE1?	NITQUYoyPTZzNUWxNi=>
MDA-MB-231	MnjIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		M1zUTFczKGh?	MV;EUXNQ	NXTlbXBwUUN3ME2wMlAyOiEQvF2=	NVXaXm5YOTV4MUW1NVI>
Hs578T	Mkn0R5l1d3SxeHnjJGF{e2G7		M1;4OlczKGh?	NF3SZ21FVVOR	MUTHTVUxRTBwMEOg{txO	NHHRZ4czPDBzNUOyOy=>
HMEC	MkXpR5l1d3SxeHnjJGF{e2G7		NWXU[mF[PzJiaB?=	MnXlSG1UVw>?	NFPhXHhIUTVyPUGuPEDPxE1?	NIPJcJIzPDBzNUOyOy=>
DU145	MWnDfZRwfG:6aXOgRZN{[Xl?		MmnxO\|IhcA>?	MmPJSG1UVw>?	M3nweGdKPTB;MD6xOkDPxE1?	MmPXNlQxOTV\|Mke=
U251	NV20bYNqS3m2b4TvfIlkKEG\|c3H5		MYW3NkBp	NY[zNnVTTE2VTx?=	MmDZS2k2OD1{LkixJO69VQ>?	MnPsNlQxOTV\|Mke=
NCI60	MnPvR5l1d3SxeHnjJGF{e2G7		NWDwW\|BJPzJiaB?=	NEjyN2NFVVOR	MUHHTVUxRTVwNzFOwG0>	MUmyOFAyPTN{Nx?=
MALME-3M	MlvYR5l1d3SxeHnjJGF{e2G7		NGDmSFI4OiCq	NYPIPVNnTE2VTx?=	MVzHTVUxRTZwNkGg{txO	M4rKVVI1ODF3M{K3
KM12	MYjDfZRwfG:6aXOgRZN{[Xl?		NFPuUpU4OiCq	NHfCeIVFVVOR	NFPkZpJIUTVyPUeuOFQh\|ryP	M1rDXlI1ODF3M{K3
SW620	M1\hOWN6fG:2b4jpZ{BCe3OjeR?=		MmLmO\|IhcA>?	MnzpSG1UVw>?	NYTKfVhJT0l3ME24MlQ{KM7:TR?=	MWeyOFAyPTN{Nx?=
RXF 393NL	Ml;JR5l1d3SxeHnjJGF{e2G7		MkjWOEBl[Xm\|	MkP0SG1UVw>?	NH3adpVKSzVyPUCuNFIyPyEQvF2=	NGW4RYozOzJ3M{C3OC=>
LXFA 983L	MULDfZRwfG:6aXOgRZN{[Xl?		MYq0JIRigXN?	M4OwW2ROW09?	Mn3kTWM2OD1yLkC1OlUh\|ryP	MVKyN\|I2OzB5NB?=
PRXF DU145	NHfIRnFEgXSxdH;4bYMhSXO\|YYm=		Mm[4OEBl[Xm\|	NGjp[olFVVOR	NFj6OFdKSzVyPUCuNFYzOyEQvF2=	MkjMNlMzPTNyN{S=
PAXF 1657L	MVzDfZRwfG:6aXOgRZN{[Xl?		MYq0JIRigXN?	NGq3NGFFVVOR	NEfFRVFKSzVyPUCuNVIyKM7:TR?=	NHzlVWczOzJ3M{C3OC=>
CXF 1103L	MXvDfZRwfG:6aXOgRZN{[Xl?		NEH1d4s1KGSjeYO=	MkHxSG1UVw>?	MoC4TWM2OD12LkO2JO69VQ>?	MkmzNlMzPTNyN{S=
GXF251L	NUm2V3RIS3m2b4TvfIlkKEG\|c3H5		NXK1[XNGPCCmYYnz	Mkm3SG1UVw>?	M4iyNGlEPTB;Mj6yOUDPxE1?	M{W1WFI{OjV\|MEe0
NCI-H23	M1L1UWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MUK3NkBp	M3vpe2ROW09?	MW\JR\|UxRTJwMkeg{txO	NHLueoczOzV{MUCyNC=>
HCT116	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		M1W5SFczKGh?	MXTEUXNQ	NUOzXYpNUUN3ME2yMlMh\|ryP	Mn7qNlM2OjFyMkC=
MCF7	MnHBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MlGxO\|IhcA>?	NXXpeHBqTE2VTx?=	M2PoVmlEPTB;Mj61O{DPxE1?	NF32fVAzOzV{MUCyNC=>
NCI-H460	NIP4ToRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NFLwe5A4OiCq	M4nCPWROW09?	MoHqTWM2OD16Lkm5JO69VQ>?	Ml;kNlM2OjFyMkC=
DLD1	MnvtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NUfJPHQ{PzJiaB?=	NYfofGQ{TE2VTx?=	NWrOcHFvUUN3ME20MlYh\|ryP	NFTIfnEzOzV4N{m2NC=>
NCI-H661	NFTZ[\|ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MYW3NkBp	NWjMWXJxTE2VTx?=	NG[0dJRKSzVyPUeuPEDPxE1?	NGnTfJgzOzV4N{m2NC=>
A549	NVnOXm1nT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NYLWOHd[PzJiaB?=	NIjPNo5FVVOR	MYjJR\|UxRThwMjFOwG0>	MYOyN\|U3Pzl4MB?=
U937	M2DjN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NXnJPZFvPzJiaB?=	M{fiW2ROW09?	MlLXTWM2OD1zMj6yJO69VQ>?	NWGxXZJlOjN3Nke5OlA>
HEK293	NF7BVHlHfW6ldHnvckBCe3OjeR?=	M1HNPFExyqEQvF2=		NUj4Zpl[TE2VTx?=	MY\JcoR2[2W\|IHLpcoRqdmdiYX\mbY5qfHlidH:gbJVu[W5iZoXscE1t\W6pdHigTIl{NXSjZ3fl[EBOgXRzIHvpcoF{\SCneIDy[ZN{\WRiaX6gTGVMOjl\|IHPlcIx{KHerdHigTWM2OCCxZjCwMlA3O87:TR?=	M{LFOlIzPzdyNkGw
HUVEC	NH\jSVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3XLXVAvOTYEoN88US=>	NX3aZm42PzJiaB?=	NWrscZNsTE2VTx?=	MWXJcoR2[2W\|IHHueIlidmerb3flcolkKGGldHn2bZR6KGmwIFjVWmVEKGOxLXP1cJR2emWmIIfpeIghfmG\|Y4XsZZIhe22xb4ToJI12e2OuZTDj[YxteyCjc4Pld5Nm\CCjczDJcohq[mm2aX;uJI9nKGOnbHyg[5Jwf3SqIHH0JFAvOTVidV2=	NV7xc3FwOjJ6NUO5PVM>
HUVEC	Ml;LSpVv[3Srb36gRZN{[Xl?	NIrEUFAyPcLizszN	M3i3bFczKGh?	M3jvRWROW09?	NUnMS3VtUW6mdXPld{BidnSrYX7nbY9o\W6rYzDhZ5Rqfmm2eTDpckBJXV[HQzDjc{1kfWy2dYLl[EB4cXSqII\hd4N2dGG{IIPtc491cCCvdYPjcIUh[2WubIOgZZN{\XO\|ZXSgZZMhUW6qaXLpeIlwdiCxZjDu[ZR4d3KtIH\vdo1ifGmxbjDheEAyNjhidH:gNVUhfU1?	NVz2eJNUOjJ6NUO5PVM>
Plasmodium falciparum	M3vHWWZ2dmO2aX;uJGF{e2G7	M{XxbVExyqEQvF2=	NVL5WYN{OTVibXnu	NXLY[Is1TE2VTx?=	MVXJcohq[mm2czDQcIF{dW:maYXtJIZidGOrcHHyeY0heHKxbHnm[ZJifGmxbjDifUBqdmirYnn0bY5oKHSqZTDGeY5kfGmxbjDv[kBR\kOGUFuxJJBzd3SnaX6ge4l1cCCLQ{WwJI9nKDFwMUhOwG0>	MVqyOFU2ODN\|MB?=
PC3	Mn2xSpVv[3Srb36gRZN{[Xl?	MV[wMlEh\|ryP	M3myU\|UhcA>?	M1HRTmROW09?	MWLJcohq[mm2czDoeY1idiCSQ{OgZ4VtdCCjZHjld4lwdiCjdDCxNFAhdk1?	NFXUc3UyQTR4Mkm3OS=>
DU145	MVjGeY5kfGmxbjDBd5NigQ>?	MVOwMlEh\|ryP	MnnXOUBp	NUDIUpV6TE2VTx?=	NFPOSo1KdmirYnn0d{BpfW2jbjDEWVE1PSClZXzsJIFlcGW\|aX;uJIF1KDFyMDDuUS=>	M3LiWVE6PDZ{OUe1
PC3	M3n6OGtqdmG\|ZTDBd5NigQ>?	MlGyNE4yKM7:TR?=	MYW1JIg>	NYLFcmFiTE2VTx?=	MX3Jcohq[mm2czDjV5JkKGmwIHj1cYFvKFCFMzDj[YxteyCjc4Pld5Nm\CCjczDy[YR2[3Srb36gc4YheGixc4Doc5J6dGG2ZXSgV5JkKFl2MU[gcIV3\WxiYYSgNVAxKG6P	NHzmdVAyQTR4Mkm3OS=>
DU145	NFHRXo1McW6jc3WgRZN{[Xl?	NGXHWYgxNjFizszN	NH7i[2E2KGh?	M3HpSmROW09?	NX3tdWoyUW6qaXLpeJMh[1O{YzDpckBpfW2jbjDEWVE1PSClZXzsd{Bie3Onc4Pl[EBieyC{ZXT1Z5Rqd25ib3[gdIhwe3Cqb4L5cIF1\WRiU4LjJHk1OTZibHX2[Ywh[XRiMUCwJI5O	NWXKbJRVOTl2NkK5O\|U>
PC3	NGXDN4VMcW6jc3WgRZN{[Xl?	NFe2c2cxNjFizszN	MmPSOUBp	NHztPHlFVVOR	M1L4U2lvcGmkaYTzJINUemNiaX6gbJVu[W5iUFOzJINmdGy\|IHHzd4V{e2WmIHHzJJJm\HWldHnvckBw\iCyaH;zdIhwenmuYYTl[EBHSUtiWUW3Ok9[PTd5IHzleoVtKGG2IEGwNEBvVQ>?	NVP5cpVMOTl2NkK5O\|U>
DU145	NFewWoxMcW6jc3WgRZN{[Xl?	M2jSW\|AvOSEQvF2=	MUK1JIg>	MV;EUXNQ	M{fER2lvcGmkaYTzJINUemNiaX6gbJVu[W5iRGWxOFUh[2WubIOgZZN{\XO\|ZXSgZZMhemWmdXP0bY9vKG:oIIDoc5NxcG:{eXzheIVlKE[DSzDZOVc3N1l3N{egcIV3\WxiYYSgNVAxKG6P	M2HaelE6PDZ{OUe1
Huh7	NXzsOoNtSW62aY\pdoFtKEG\|c3H5	Ml3yNk42KM7:TR?=	MonQOEBl[Xm\|	NHjBR3FFVVOR	M{jOe2lvcGmkaYTzJJZqemGuIIPwdoVi\CCrbjDE[Y5ofWVidnnyeZMucW6oZXP0[YQhcHWvYX6gTJVpPyClZXzsd{Bie3Onc4Pl[EBieyCjY3P1cZVt[XSrb36gc4Yhfmm{YXyg[Y53\WyxcHWgdJJwfGWrbjD3bZRpcW5icHXybY52[2ynYYKgdoVocW:wIHH0JFIvPSC3TR?=	MWixO\|M3ODZ5Nh?=
C6/36	NHH2cm1CdnSrdnnyZYwhSXO\|YYm=	Mlj4Nk42KM7:TR?=	NWn5XlBVPCCmYYnz	NED6eo5FVVOR	NFznfpFKdmirYnn0d{B3cXKjbDDzdJJm[WRiaX6gSIVv\3WnII\pdpV{NWmwZnXjeIVlKGG\|aXHuJJRq\2W{IH3vd5F2cXSxIFO2M\|M3KGOnbHzzJIF{e2W\|c3XkJIF{KGGlY4XteYxifGmxbjDv[kB3cXKjbDDlcpZmdG:yZTDwdo91\WmwIIfpeIhqdiCyZYLpcpVkdGWjcjDy[Ydqd25iYYSgNk42KHWP	MmfLNVc{PjB4N{[=
U937	MkjUSpVv[3Srb36gRZN{[Xl?	MUKxJO69VQ>?	MlH1NUBp	MojaSG1UVw>?	NH3BTI9T\WS3Y3XzJIJie2GuIGTOSoFteGijIILlcIVie2ViaX6gbJVu[W5iVUmzO{Bk\Wyucx?=	NGX6d\|EyPzZ6NEC5PS=>
U937	NFX1SVBHfW6ldHnvckBCe3OjeR?=	M33Hb\|Eh\|ryP	NX3NSHpUOSCq	MnjuSG1UVw>?	MXLS[YR2[2W\|IFzQV{1qdmS3Y3XkJHRPTmGucHjhJJJmdGWjc3WgbY4hcHWvYX6gWVk{PyClZXzsdy=>	MX[xO\|Y5PDB7OR?=
murine mast cell	MkD3SpVv[3Srb36gRZN{[Xl?	NGr5d2QyKM7:TR?=	MVqyOEBp	Mm\NSG1UVw>?	MWPJcohq[mm2czDhcpRq\2WwLXnu[JVk\WRiSVy2JJNm[3KndHnvckBqdiCLZ1WgdJJqdWWmIH3veZNmKG2jc4SgZ4VtdHNiYYSgNUB2VQ>?	MYmxO\|Y5PDB7OR?=
BV-173	M3\wOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MmX3TWM2OD1yLkCwNFAxODFyOTFOwG0>	MoW0V2FPT0WU
K-562	Ml6zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4SzR2lEPTB;MD6wNFAxODB{Nk[g{txO	M3XNTHNCVkeHUh?=
BL-70	NVmyVWhQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXnlSWsyUUN3ME2wMlAxODByMEiyNkDPxE1?	MY\TRW5ITVJ?
EM-2	Mm\NS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVXJR\|UxRTBwMECwNFAyODhizszN	NV\JXJc6W0GQR1XS
LAMA-84	NXjZVHlmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MUTJR\|UxRTBwMECwNFA{OjFizszN	MoO5V2FPT0WU
MEG-01	NFvnXXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmWzTWM2OD1yLkCwNFAxQThizszN	M2jROnNCVkeHUh?=
EoL-1-cell	MkPCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MULJR\|UxRTBwMECwNFE{OSEQvF2=	NIXrRZpUSU6JRWK=
CTV-1	M2Ph[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NIHHW49KSzVyPUCuNFAxODRyNDFOwG0>	NHjjSWhUSU6JRWK=
TE-15	M2TqeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2f5[GlEPTB;MD6wNFU5QSEQvF2=	M3jDbHNCVkeHUh?=
NOS-1	MmqwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWP0fplpUUN3ME2wMlAxPjF\|IN88US=>	NUXuflBkW0GQR1XS
D-336MG	NEC0S4xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NUnVdmExUUN3ME2wMlAxPjNizszN	NEWwNoRUSU6JRWK=
LB1047-RCC	NYfoU\|dnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWDJR\|UxRTBwMEC5PFkh\|ryP	NFXFfIdUSU6JRWK=
LB996-RCC	Ml\nS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHPQSolKSzVyPUCuNFA6QTFizszN	Mn;lV2FPT0WU
SW982	NV;NdYNDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M17DTWlEPTB;MD6wNVEyPSEQvF2=	NH7nWJpUSU6JRWK=
TK10	M2L3e2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWXUXVZrUUN3ME2wMlAyOTd2IN88US=>	MlXTV2FPT0WU
A704	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MUTJR\|UxRTBwMEG0PVEh\|ryP	NUPRbIk2W0GQR1XS
TE-8	MkPBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MUjJR\|UxRTBwMEG1O\|Yh\|ryP	NFm2eW1USU6JRWK=
DOHH-2	NUPvV4RnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYrJR\|UxRTBwMEG3NVkh\|ryP	NIDjbHJUSU6JRWK=
HOP-62	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2LXfGlEPTB;MD6wNVg{PCEQvF2=	MWLTRW5ITVJ?
TE-12	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{fvN2lEPTB;MD6wNVg3OSEQvF2=	NVizSo94W0GQR1XS
KGN	NX\xOHZFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NEHFZ\|FKSzVyPUCuNFE6PDJizszN	MnXxV2FPT0WU
NCI-H1648	M1XwNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MoLYTWM2OD1yLkCyNFEyKM7:TR?=	MlfiV2FPT0WU
OS-RC-2	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NU\oO3p7UUN3ME2wMlAzODNizszN	NYfZ[nZOW0GQR1XS
GB-1	NFq4bppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYLJR\|UxRTBwMEKxOVch\|ryP	NXL3XY9EW0GQR1XS
RXF393	M371Z2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYDDRlZLUUN3ME2wMlAzOzV5IN88US=>	NUn6Z5BoW0GQR1XS
LC-2-ad	MlGyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NIXxT49KSzVyPUCuNFI2QDZizszN	MlKzV2FPT0WU
KS-1	M3\MXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2TiNmlEPTB;MD6wNlc{KM7:TR?=	NXWyTIhOW0GQR1XS
ETK-1	NEHtR5FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGXo[YNKSzVyPUCuNFI5OzJizszN	M3rTPXNCVkeHUh?=
SW954	NGXzPFRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXj2UGV5UUN3ME2wMlAzQTJ5IN88US=>	MkOwV2FPT0WU
Becker	NHnXUHhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVS1WoJWUUN3ME2wMlA{ODB\|IN88US=>	NWLjc4dCW0GQR1XS
MZ1-PC	MmLkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{LnXmlEPTB;MD6wN\|EyQSEQvF2=	MX3TRW5ITVJ?
ES6	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NV63bnh4UUN3ME2wMlA{OTl\|IN88US=>	NFrDOJRUSU6JRWK=
KURAMOCHI	NYTofFdYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYnJR\|UxRTBwMEO0PFch\|ryP	MUfTRW5ITVJ?
CGTH-W-1	NYnZZVNUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1zCS2lEPTB;MD6wN\|U1QCEQvF2=	MnL4V2FPT0WU
VA-ES-BJ	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NX7uc\|ZQUUN3ME2wMlA{QTB{IN88US=>	NYPySZVWW0GQR1XS
LXF-289	MmjCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2jNdWlEPTB;MD6wN\|k2PiEQvF2=	NYX6Zmh6W0GQR1XS
MPP-89	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NELY[nFKSzVyPUCuNFQxPDlizszN	MV;TRW5ITVJ?
SW872	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NV7VeHY1UUN3ME2wMlA1OTZzIN88US=>	MVvTRW5ITVJ?
SNB75	MlfIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NH\DbJlKSzVyPUCuNFQ1OzVizszN	M2jObHNCVkeHUh?=
PSN1	MlHPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2LFWmlEPTB;MD6wOFQ4PCEQvF2=	Mn60V2FPT0WU
LB831-BLC	NV;OXoxST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MoO1TWM2OD1yLkC0OlA6KM7:TR?=	MVPTRW5ITVJ?
MFH-ino	NGXTU5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHK5OmdKSzVyPUCuNFQ4OjRizszN	NHHaO4NUSU6JRWK=
TGBC24TKB	M4DrXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NEjudYxKSzVyPUCuNFQ4PjFizszN	MlnsV2FPT0WU
A388	MoDkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFHBfo5KSzVyPUCuNFUxQTVizszN	MkexV2FPT0WU
BB30-HNC	NVXCc3VDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NUX1VXZSUUN3ME2wMlA2PDN5IN88US=>	M3LNRXNCVkeHUh?=
GI-ME-N	MlPOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NEe4b\|NKSzVyPUCuNFYyOThizszN	MnPsV2FPT0WU
TGBC1TKB	NVfsZlRST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MkLuTWM2OD1yLkC2NVY1KM7:TR?=	NGL6SIJUSU6JRWK=
TE-10	M4rueGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NEPYV2lKSzVyPUCuNFY{PTdizszN	MnvCV2FPT0WU
A498	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NEiyT3NKSzVyPUCuNFczQDRizszN	MmnJV2FPT0WU
TE-11	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHzkb4JKSzVyPUCuNFc5PThizszN	M2HNcnNCVkeHUh?=
BB65-RCC	NX7obIdbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1HlR2lEPTB;MD6wPFIzPyEQvF2=	NET1dYhUSU6JRWK=
C2BBe1	Ml;1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2XMfmlEPTB;MD6wPFMxQCEQvF2=	NXTrToFGW0GQR1XS
NCI-H747	NVn3[\|ZMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3;ofGlEPTB;MD6wPFM3OiEQvF2=	NUixV5ltW0GQR1XS
IST-MES1	NVrhV5ZXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWOweGlHUUN3ME2wMlA5PTV{IN88US=>	MVXTRW5ITVJ?
KALS-1	MlfGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3HJcWlEPTB;MD6wPVQ6KM7:TR?=	MUDTRW5ITVJ?
GCIY	NYr6XpgyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYTJR\|UxRTBwMEm2OVYh\|ryP	NU\Be\|VmW0GQR1XS
RL95-2	M3Lwd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVzFV4hsUUN3ME2wMlExOzhizszN	NWj3ZlZyW0GQR1XS
TE-1	MmLtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1XxNGlEPTB;MD6xNFU1KM7:TR?=	MYfTRW5ITVJ?
NCI-H1355	MmX2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXzPVopmUUN3ME2wMlEyODJ6IN88US=>	MYTTRW5ITVJ?
SW962	M{D4SGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NX3kVnF{UUN3ME2wMlEyOjl{IN88US=>	M3HCR3NCVkeHUh?=
KLE	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NX71V\|V6UUN3ME2wMlEyOzF5IN88US=>	MYnTRW5ITVJ?
MC116	Mm\uS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGDwSVBKSzVyPUCuNVE1OSEQvF2=	NEm4Z49USU6JRWK=
NMC-G1	Mli3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXfzfWh5UUN3ME2wMlEyPjB4IN88US=>	NGTNe5JUSU6JRWK=
KU812	M3PPZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MlTCTWM2OD1yLkGxPFg{KM7:TR?=	M37MdnNCVkeHUh?=
COLO-829	NVjuOGlPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{fWTGlEPTB;MD6xNlIyOyEQvF2=	Mk\5V2FPT0WU
NTERA-S-cl-D1	MmHiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MkPTTWM2OD1yLkGyNlg{KM7:TR?=	NYDlSZplW0GQR1XS
IST-MEL1	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NH24d3BKSzVyPUCuNVM1PSEQvF2=	MmLFV2FPT0WU
MLMA	NYXnVpZLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1vzWmlEPTB;MD6xOFA{OiEQvF2=	MkPOV2FPT0WU
LS-123	M1XCemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NIHIdVRKSzVyPUCuNVQxPjRizszN	NXy0VG5EW0GQR1XS
LB2518-MEL	NHTnbnhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2WzS2lEPTB;MD6xOFE3OiEQvF2=	MkPWV2FPT0WU
NB69	NXzKSVdXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MV7JR\|UxRTBwMUS0N\|Yh\|ryP	MXzTRW5ITVJ?
8-MG-BA	M{HTUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MX7JR\|UxRTBwMUW0OVgh\|ryP	NIHB[VBUSU6JRWK=
K5	MlLxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHrHTWJKSzVyPUCuNVY1QDlizszN	MVnTRW5ITVJ?
KINGS-1	NH\wdpBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFnGRZpKSzVyPUCuNVY3PjZizszN	M1jaT3NCVkeHUh?=
SF268	M13Rb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Ml\0TWM2OD1yLkG3OFA1KM7:TR?=	NGK3TVZUSU6JRWK=
PF-382	NIjze2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVzJR\|UxRTBwMUe2O\|gh\|ryP	MWrTRW5ITVJ?
SH-4	NXT2XWVyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NV\POGp4UUN3ME2wMlE5PDF\|IN88US=>	NV\Vc3NkW0GQR1XS
NALM-6	MoXSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mm[4TWM2OD1yLkG5Nlk2KM7:TR?=	MV7TRW5ITVJ?
CP66-MEL	NXjBcY9{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{n3XGlEPTB;MD6xPVU{OSEQvF2=	MV3TRW5ITVJ?
697	NEizemZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MUPJR\|UxRTBwMUm5PFch\|ryP	MlriV2FPT0WU
CP67-MEL	M4LXNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4HKRmlEPTB;MD6yNFQ5QCEQvF2=	M1nxXHNCVkeHUh?=
DSH1	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlP6TWM2OD1yLkK0NFAyKM7:TR?=	NWDPRXZQW0GQR1XS
HCE-4	NHHqemNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1LrO2lEPTB;MD6yOlQ{QSEQvF2=	MWLTRW5ITVJ?
MZ2-MEL	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NV;yXFA4UUN3ME2wMlI5PTN5IN88US=>	M4PBPHNCVkeHUh?=
BL-41	NIf0b25Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYrJR\|UxRTBwMkmxNlMh\|ryP	NH\kOldUSU6JRWK=
HUTU-80	MmfLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYnJR\|UxRTBwM{G0NkDPxE1?	NULMfGpOW0GQR1XS
LOXIMVI	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1XQVmlEPTB;MD6zNVUxOyEQvF2=	MnrFV2FPT0WU
no-10	NYTUfYZUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MV3JR\|UxRTBwM{G5N\|Eh\|ryP	M3XiZXNCVkeHUh?=
KARPAS-422	NYfBOJBLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFm4OYhKSzVyPUCuN\|M6QTdizszN	MmLkV2FPT0WU
SW684	M2\XbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHrteZVKSzVyPUCuN\|Q6QCEQvF2=	NELaN5pUSU6JRWK=
SF126	NXT4fnBET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Ml;MTWM2OD1yLkO1OFEh\|ryP	MoG0V2FPT0WU
D-263MG	MnLUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVLJNm96UUN3ME2wMlM3OjJ2IN88US=>	M1XQ[XNCVkeHUh?=
OVCAR-4	M2LoT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NEPsd3JKSzVyPUCuN\|c1OzNizszN	NHfkdFhUSU6JRWK=
BB49-HNC	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NIf6SoZKSzVyPUCuN\|g2QTlizszN	NVzBU29XW0GQR1XS
ONS-76	NYnnb\|B6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXTZNXR7UUN3ME2wMlQzQTVzIN88US=>	MWXTRW5ITVJ?
MZ7-mel	NWToNFd{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MoPBTWM2OD1yLkS3PVEyKM7:TR?=	NGLycGNUSU6JRWK=
RCC10RGB	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1LXUWlEPTB;MD60PVEyKM7:TR?=	NVHOdnZYW0GQR1XS
BOKU	NGDpN5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NEDyNGZKSzVyPUCuOFkyOzNizszN	NIL5doJUSU6JRWK=
no-11	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWrJR\|UxRTBwNUCyNlgh\|ryP	MkT5V2FPT0WU
IST-SL2	M4\q[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2jKb2lEPTB;MD61NFMxOiEQvF2=	NHPjc5pUSU6JRWK=
RKO	NEfYcZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnvRTWM2OD1yLkWyPVY3KM7:TR?=	NFTIcHJUSU6JRWK=
HT-144	NHHTVJdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M13ESWlEPTB;MD61N\|YxQSEQvF2=	NF\xWXNUSU6JRWK=
NCI-H446	MnjqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVXkeJZGUUN3ME2wMlYzPzZizszN	M37aN3NCVkeHUh?=
QIMR-WIL	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NH\obYxKSzVyPUCuO\|A3OjlizszN	NVrpO4xoW0GQR1XS
MHH-PREB-1	M3nFfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGryO25KSzVyPUCuO\|Q1PjlizszN	MUPTRW5ITVJ?
EW-16	NVjvblBIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWrJR\|UxRTBwN{[xO\|gh\|ryP	NFzYVG5USU6JRWK=
EW-24	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXPJR\|UxRTBwN{ixOlUh\|ryP	NH\W[3pUSU6JRWK=
LB373-MEL-D	M1q2V2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mk\nTWM2OD1yLkiyOVA5KM7:TR?=	MkPvV2FPT0WU
TE-9	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXTJR\|UxRTBwOEe1N\|Ih\|ryP	M{T1cnNCVkeHUh?=
A3-KAW	M{nPN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXnJR\|UxRTBwOUi0OVIh\|ryP	NYH5VlN5W0GQR1XS
A101D	NVX6d4VLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFjCbnRKSzVyPUGuNFMxPDNizszN	NETFOHdUSU6JRWK=
OCUB-M	NXi3fFR1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mn\yTWM2OD1zLkC0OFEzKM7:TR?=	NEjIfFFUSU6JRWK=
ES4	NInrdG9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYHJR\|UxRTFwMEWxOFUh\|ryP	MlPzV2FPT0WU
TE-6	NIrZ[Y9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NF\IeWpKSzVyPUGuNlEzOjZizszN	M{DheHNCVkeHUh?=
D-502MG	MmCwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXPJR\|UxRTFwMkOzO\|Yh\|ryP	M2jhe3NCVkeHUh?=
KNS-42	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFrzbWJKSzVyPUGuNlQ1OTJizszN	M3;JcXNCVkeHUh?=
SNU-C2B	NVfpNW5[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MoTZTWM2OD1zLkOwOVg6KM7:TR?=	MVLTRW5ITVJ?
NCI-H1838	M3vONWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NUDqXoF2UUN3ME2xMlMxPzN\|IN88US=>	M1;n[HNCVkeHUh?=
NKM-1	NInqOYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYHJR\|UxRTFwM{C4OVkh\|ryP	MoHLV2FPT0WU
GI-1	M3jyc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2XCfGlEPTB;MT6zOlIzKM7:TR?=	MX;TRW5ITVJ?
NB5	M3vnN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGHFSZRKSzVyPUGuN\|k5OjdizszN	NIfCe4FUSU6JRWK=
CAS-1	M1HMRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHqxcJlKSzVyPUGuOFA6QTJizszN	M3\Ec3NCVkeHUh?=
HCE-T	M3zuZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWfLb4JDUUN3ME2xMlU3PzF2IN88US=>	NVzQUZhxW0GQR1XS
SBC-1	NEXpZlBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFXUc\|VKSzVyPUGuOVc6QDRizszN	M3TUXXNCVkeHUh?=
JiyoyeP-2003	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NX7UXo1vUUN3ME2xMlc{PDZ4IN88US=>	NXqwfoxpW0GQR1XS
TE-5	M1n2SGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MmHoTWM2OD1zLke5NVM6KM7:TR?=	NGLGR4xUSU6JRWK=
CAN	MoD0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3fNcGlEPTB;MT64NlI2OiEQvF2=	M4ruPXNCVkeHUh?=
SK-UT-1	NVXxXms{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3jLS2lEPTB;Mj6xOlY6OyEQvF2=	NGnkSYhUSU6JRWK=
JVM-2	M2PwR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mm\VTWM2OD1{LkO2Nlg1KM7:TR?=	NYDqdHRiW0GQR1XS
LB771-HNC	NITwbGtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVzXVldyUUN3ME2yMlU4PTVzIN88US=>	Mk\DV2FPT0WU
NCCIT	NWfnTHU1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFHKcmlKSzVyPUKuPFY3OTZizszN	MUnTRW5ITVJ?
NCI-H2126	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NIDh[lJKSzVyPUKuPFc2PTJizszN	MX3TRW5ITVJ?
Calu-6	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVPJR\|UxRTNwMEW3OFEh\|ryP	NELBbJFUSU6JRWK=
SK-LMS-1	NUDSVpRQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NEmzW2RKSzVyPUOuNVE5QDZizszN	M2PzcHNCVkeHUh?=
ARH-77	MlvxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1;zTmlEPTB;Mz60OlkyPSEQvF2=	MnHPV2FPT0WU
NB17	NGrESIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2XzNGlEPTB;Mz62N\|g1PyEQvF2=	MnTRV2FPT0WU
A253	NHHsWFRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYPXSnBQUUN3ME2zMlc{OjR4IN88US=>	NUnYV4o1W0GQR1XS
OPM-2	NXG4OZQ{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWnJR\|UxRTRwMke2PFUh\|ryP	MV7TRW5ITVJ?
MV-4-11	M2fxOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{LGeWlEPTB;ND6zOlQ2PCEQvF2=	MY\TRW5ITVJ?
SR	NULtNoU{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmCwTWM2OD12LkS5PVU1KM7:TR?=	Ml3VV2FPT0WU
KG-1	NFjkTpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2f2W2lEPTB;ND62NFg1PSEQvF2=	NGmwellUSU6JRWK=
OCI-AML2	NX74XZNIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlzzTWM2OD13Lki2NVU1KM7:TR?=	NFzvWnZUSU6JRWK=
D-247MG	M3zETmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MkfNTWM2OD14LkGyOVE6KM7:TR?=	Mof3V2FPT0WU
DJM-1	NYDUN\|l{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVrJR\|UxRTZwNEi1OVgh\|ryP	NH\RcG1USU6JRWK=
RPMI-6666	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYTRTFZoUUN3ME23MlI4ODZ5IN88US=>	Mlj6V2FPT0WU
KARPAS-45	M1rwRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYXJR\|UxRTdwNUG2O\|Eh\|ryP	NFjncpdUSU6JRWK=
LP-1	NI\MfGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYDJR\|UxRTdwNUS3PFIh\|ryP	MkDXV2FPT0WU
RS4-11	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXjFTnp5UUN3ME23MlY2Pzh5IN88US=>	MmLZV2FPT0WU
DU-4475	NFiyR\|FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVjzSWVSUUN3ME24MlIyPjV{IN88US=>	Mn7tV2FPT0WU
MONO-MAC-6	MlTMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYLsdIt{UUN3ME24MlI4ODZ4IN88US=>	NU\qeWlZW0GQR1XS
NCI-SNU-16	MmrsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NInlN2FKSzVyPUiuOVYyOjhizszN	M4fvdXNCVkeHUh?=
SJSA-1	M4rHbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYrJR\|UxRThwN{K4NFUh\|ryP	NYPLOoM6W0GQR1XS
MMAC-SF	Ml76S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mn;tTWM2OD16Lke5N\|A4KM7:TR?=	NUHaNmNVW0GQR1XS
SK-NEP-1	NHXGbXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mn3hTWM2OD16Lki5NVU2KM7:TR?=	MmHBV2FPT0WU
J-RT3-T3-5	NG\a[WdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MX7JR\|UxRThwOU[1Nlkh\|ryP	Mn\NV2FPT0WU
SKM-1	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MknrTWM2OD17LkCxO\|M1KM7:TR?=	NH:ydIlUSU6JRWK=
LB2241-RCC	M4e1S2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXHqdYZmUUN3ME25MlAzODF{IN88US=>	NFTZcIpUSU6JRWK=
SIG-M5	NYD1dHBnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MUXJR\|UxRTlwMEK0PVMh\|ryP	MlqwV2FPT0WU
EVSA-T	NYGzXWZbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGH0WldKSzVyPUmuNlc4QTNizszN	MmT4V2FPT0WU
GT3TKB	MmDHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4jISWlEPTB;OT6zOVU1PiEQvF2=	NX3UeVU4W0GQR1XS
NB6	MlTBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYfJR\|UxRTlwOUKyOVkh\|ryP	M{PQb3NCVkeHUh?=
EHEB	NVHpS41rT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVTtOoZ5UUN3ME2xNE4xPjV4IN88US=>	M2[4e3NCVkeHUh?=
HEL	NXf1TnRjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MV3JR\|UxRTFyLkS3O\|Yh\|ryP	MojKV2FPT0WU
ALL-PO	M4j3[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1rlcGlEPTB;MUCuO\|k{QCEQvF2=	M4nuc3NCVkeHUh?=
TGW	NHHxXnJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4PRSmlEPTB;MUGuNlgzQCEQvF2=	MVTTRW5ITVJ?
BC-3	MkHGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3vBd2lEPTB;MUKuNVE{QCEQvF2=	M3HWc3NCVkeHUh?=
IA-LM	NGi3e3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVHJR\|UxRTF{LkS0OFUh\|ryP	MX3TRW5ITVJ?
UACC-257	NV7N[4pET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3zkSWlEPTB;MUKuPVE6QCEQvF2=	MVfTRW5ITVJ?
KP-N-YS	NFm1N4dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{\3NGlEPTB;MUKuPVI5OyEQvF2=	NIe3XHdUSU6JRWK=
Raji	NIi1bllIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlS1TWM2OD1zMz63OFk4KM7:TR?=	M1f5e3NCVkeHUh?=
SF539	NUKxb2g6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWLpNoNnUUN3ME2xN{45PTV5IN88US=>	NX3hfnZJW0GQR1XS
DMS-153	MkT6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MV\JR\|UxRTF2LkCwNlgh\|ryP	MnL2V2FPT0WU
L-540	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4\UT2lEPTB;MUWuNFY4OiEQvF2=	MX3TRW5ITVJ?
MN-60	Mn:wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MonUTWM2OD1zNT6xPVc6KM7:TR?=	NWXuTW1YW0GQR1XS
RPMI-8866	MojPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MmD2TWM2OD1zNz60OFU1KM7:TR?=	NGnMXZlUSU6JRWK=
NCI-H510A	NVfYdmE4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M13Q[mlEPTB;MUmuN\|k4OyEQvF2=	MXzTRW5ITVJ?
NB13	NUfaNHZFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnW2TWM2OD1zOT60PFc4KM7:TR?=	MUfTRW5ITVJ?
HAL-01	Mli0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnXRTWM2OD1zOT63OVQ{KM7:TR?=	MWPTRW5ITVJ?
NCI-H720	M{XycWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXzzTGp4UUN3ME2yNE4zPzN\|IN88US=>	NH7jTnlUSU6JRWK=
REH	M1fNemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mk\LTWM2OD1{MD62N\|U4KM7:TR?=	MVTTRW5ITVJ?
KNS-81-FD	NFLR[FhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Ml;xTWM2OD1{Mz6xOFYh\|ryP	MVjTRW5ITVJ?
HC-1	MkW5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MY\JR\|UxRTJ2LkW1OVEh\|ryP	NXP3Xo1bW0GQR1XS
NCI-H2141	NFjJdoxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NV\1PJN1UUN3ME2yOE44PzV2IN88US=>	Mnn1V2FPT0WU
MOLT-4	M33UPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFnwXXZKSzVyPUK2MlY4PTNizszN	NFGxdmRUSU6JRWK=
OMC-1	M3rHO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MV;JR\|UxRTJ5LkG0NlIh\|ryP	MYLTRW5ITVJ?
LC-1F	Mof1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MmrtTWM2OD1{Nz6zNlQ2KM7:TR?=	M{LHcnNCVkeHUh?=
NCI-H1304	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{fYbWlEPTB;MkiuNVYzQCEQvF2=	NHjRNIhUSU6JRWK=
BC-1	NHrzOG5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NV;nWW9oUUN3ME2yPE43PTFizszN	NVH2ZWd6W0GQR1XS
NCI-H64	M4TT[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MonoTWM2OD1{OT62NlU{KM7:TR?=	MoOwV2FPT0WU
MOLT-16	MoP6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NH7kPJlKSzVyPUK5MlYzQTJizszN	MWTTRW5ITVJ?
U-87-MG	NYOxVYZYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NED6VZJKSzVyPUOwMlc3PiEQvF2=	MUTTRW5ITVJ?
GAK	NV[3[lUyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYnJR\|UxRTNzLkK2PFYh\|ryP	MYXTRW5ITVJ?
ES8	NYnx[GhnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NV\wU5FqUUN3ME2zNk4yOjV{IN88US=>	MXvTRW5ITVJ?
HCC1599	M2TTNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MkLqTWM2OD1\|Mj6zN\|I2KM7:TR?=	NVnJT\|BkW0GQR1XS
EB-3	NEDpWndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXvJR\|UxRTN2LkOxNVch\|ryP	MlrSV2FPT0WU
HCC1187	MlXBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYrvbZVIUUN3ME2zOU45ODV{IN88US=>	NITiXGRUSU6JRWK=
SK-PN-DW	MmPJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWPlcXduUUN3ME2zOk4yQTR\|IN88US=>	MXHTRW5ITVJ?
JVM-3	M4nwbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MUXJR\|UxRTN5LkKzN\|gh\|ryP	M17PWHNCVkeHUh?=
HCC2157	NHfDeo9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1PCbWlEPTB;M{euPVk1PiEQvF2=	NXnvbVN[W0GQR1XS
A4-Fuk	M1f3TGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2\DS2lEPTB;M{iuNVAxQSEQvF2=	M2TibnNCVkeHUh?=
COR-L279	MkPxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NEnhSGFKSzVyPUSwMlI5PTFizszN	NUTldXV7W0GQR1XS
DEL	M2L6PGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MoG3TWM2OD12MT65NFg3KM7:TR?=	MVHTRW5ITVJ?
NCI-H1395	NIn5[ZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NF[0V2ZKSzVyPUSyMlAyPjNizszN	NWnBSoRFW0GQR1XS
MHH-NB-11	M{GyWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MX7JR\|UxRTR\|LkC4NVgh\|ryP	MnTBV2FPT0WU
NCI-H2107	NF21dllIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXXDe3k6UUN3ME20N{41QDR4IN88US=>	Mk\rV2FPT0WU
NEC8	Mn3tS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1znc2lEPTB;NESuN\|M3KM7:TR?=	NF3NdVFUSU6JRWK=
COLO-684	NUnvSmJ3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2XNR2lEPTB;NE[uNlI2QCEQvF2=	NVfpW3RCW0GQR1XS
LS-411N	MoW3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFS2XIRKSzVyPUS4MlQ4PDhizszN	NWiyNlFLW0GQR1XS

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	phospho-c-Abl(Tyr245) / phospho-c-Src(Tyr416); PubMed: 23049975 PLoS One Protein levels of phosphorylated c-Abl (Tyr245), c-Abl, phosphorylated c-Src (Tyr416), c-Src, and GAPDH in NSC-34 cells overexpressing human wild-type or mutant SOD1s treated with various concentrations of dasatinib were measured by western blot. Cells were cultured in serum-free culture medium with doxycycline (Dox, 2 µg/ml), and western blot was performed at 24 h after dasatinib addition. p27 / p21; PubMed: 20145167 Clin Cancer Res Dasatnib induced cell cycle arrest. Dasatinib induced growth arrest, shown as a cell cycle distribution graph in the lower panel, correlated with increased p27 and p21 levels. Western blotting for levels of p27 and p21 was performed on protein lysates of THP-1 cells treated for 48 hours with indicated doses of dasatinib or DMSO. Detection of actin served as control for comparable protein loading. p-FAK / p-STAT3; PubMed: 23721490 BMC Cancer The effect of dasatinib in cell signalling. Western blot analysis with phosphorylated Src, FAK, Stat3, Akt and MAPK in HCC cell lines after 24 hours treatment of dasatinib. The cell lines were arranged according to their IC50 to dasatinib. The top three were most sensitive, the bottom 3 were least sensitive. cleaved caspase 3; PubMed: 20145167 Clin Cancer Res Dasatinib induced apoptosis. Dasatinib causes apoptosis in Mo7e-KitD816H cells as detected by cleavage of caspase 3. Whole cell lysates were prepared after 24 hour treatment with dasatinib. Caspase 3 and cleaved capase 3 were analyzed by western blotting. Actin serves as loading control.	23049975 20145167 23721490
Growth inhibition assay	IC50; PubMed: 23721490 BMC Cancer 9 HCC cell lines were exposed to the dedicated concentrations of dasatinib for 72 hours, and IC50 was tested by MTS. Results represent the mean (± SD) of three experiments.	23721490
Immunofluorescence	SRC / Met; PubMed: 26517812 Oncotarget Immunocytochemistry of SRC and Met localization. Cellular localization of SRC and Met following treatment for 48 h with dasatinib, crizotinib or combination in A. LN-18 and B. U373 cells. Scale bar denotes 10 μm. Nuclei were visualized by DAPI while SRC and Met were labeled with a fluorescein and Texas-red conjugated secondary antibodies, respectively. F-actin / Actinin-4 / Paxillin; PubMed: 31053734 Nat Commun Conditionally immortalized differentiated podocytes treated for one-hour with 2 µM kinase inhibitor were stained for F-actin (phalloidin), α-actinin-4, paxillin, and nuclei (Hoechst 33342) to assess cytoskeletal and focal adhesion architecture (scale bars = 50 µm). Podocytes treated with dasatinib showed a marked decrease in cell-to-cell contacts, cell size and number of focal adhesions. α-tubulin; PubMed: 26517812 Oncotarget Combination of dasatinib and crizotinib impedes the formation of the α-tubulin-labeled mitotic spindle. LN-18 cells were treated with dasatinib 0.2 μM, crizotinib 4 μM or their combination for 48 h. Mitotic spindle were visualized using α-tubulin antibody conjugated to a fluorescein-labeled secondary antibody. Nuclei were stained by DAPI. The scale bar denotes 10 μm.	26517812 31053734
ELISA	TNF-α; PubMed: 17684099 Proc Natl Acad Sci U S A U937 cells were differentiated with vitamin D3, pretreated with the indicated concentrations of drugs for 1 h and stimulated with LPS for 6 h. TNF-α secretion was measured by ELISA. The graph shows the mean of two experiments done in duplicate. E-selectin; PubMed: 31110200 Sci Rep HAoECs were treated with DMSO, a dual FAK/Pyk2 inhibitor (PF-271, 2.5 μM), a Src inhibitor (Dasatinib, 1 μM), or a FAK inhibitor (PF-228, 10 μM) for 1 h prior to TNF-α (10 ng/ml, 6 h) stimulation. Expression levels of E-selectin was determined using ELISA (n = 3, ±SEM). VCAM-1; PubMed: 31110200 Sci Rep HAoECs were treated with DMSO, a dual FAK/Pyk2 inhibitor (PF-271, 2.5 μM), a Src inhibitor (Dasatinib, 1 μM), or a FAK inhibitor (PF-228, 10 μM) for 1 h prior to TNF-α (10 ng/ml, 6 h) stimulation. Expression levels of VCAM-1 was determined using ELISA (n = 3, ±SEM).	17684099 31110200

体内研究

Dasatinib 作用于LMP2A/MYC 双转基因小鼠，可逆转脾肿大。Dasatinib 作用于TgE小鼠抑制表达LMP2A 的骨髓B 细胞形成的菌落，且使脾脏变小。使用Dasatinib处理Tg6/λ-MYC 小鼠，与对照组相比，脾脏质量明显降低。Dasatinib 作用于LMP2A/MYC 双转基因小鼠，抑制淋巴结肿大。Dasatinib作用于嫁接LMP2A/MYC双转基因小鼠肿瘤细胞的Rag1KO小鼠，可逆转脾肿大。Dasatinib 作用于表达LMP2A的B 淋巴细胞瘤，抑制Lyn磷酸化。^[2]

激酶实验：^[1]	+ 展开激酶自磷酸化分析: 使用野生型和突变型谷胱甘肽S-转移酶(GST)-Abl融合蛋白 (c-Abl氨基酸220-498位) 进行激酶实验。从谷胱甘肽琼脂糖珠中释放GST-Abl融合蛋白，ATP浓度为5 μM。在用于激酶自磷酸化和体外肽底物磷酸化实验前, 用LAR酪氨酸磷酸酶处理GST-Abl 激酶域融合蛋白。在 30^oC下温育1小时后,加入1 mM 钒酸钠，激活LAR磷酸酶。进行免疫印迹分析，比较未处理的GST-Abl激酶和去磷酸化的GST-Abl激酶，使用磷酸化的特点抗体4G10来确认酪氨酸残基完全去磷酸化(>95%)，使用c-Abl抗体 CST 2862 来确认GST-Abl激酶的平衡负载。实验测定IC50值时所用Dasatinib浓度为0 nM到32 nM。Dasatinib作用于突变型T315I时浓度达到 1,000 nM。在体外肽底物磷酸化实验中使用相同抑制剂浓度。作用于GST-Src激酶和 GST-Lyn激酶的三种抑制剂的浓度范围相同。
细胞实验： ^[1]	+ 展开 Cell lines: Ba/F3细胞系 Concentrations: 0 nM-32 nM Incubation Time: 72小时 Method: Ba/F3 细胞系重复培养三份，然后与浓度逐渐升高的 Dasatinib 温育72小时。通过MTS活性实验测定细胞增殖。IC50值和IC90值取自三组独立实验的平均值。Dasatinib作用的IC50值和IC90值为0 nM 到32 nM 。Dasatinib 作用于突变型T315I时所需浓度达到200 nM。 (Only for Reference)
动物实验：^[2]	+ 展开 Animal Models: EμLMP2A(TgE 和Tg6品种),MYC (λ-MYC), 和LMP2A/λ-MYC双转基因小鼠(Tg6/λ-MYC) Formulation: DMSO Dosages: 30 mg/kg Administration: 腹腔注射 (Only for Reference)

参考文献

[4] Dargart JL, et al. Antiviral Res. 2012, 95(1), 49-56.

+ 展开

溶解度 (25°C)

体外	DMSO	98 mg/mL (200.81 mM)
	Water	Insoluble
	Ethanol	Insoluble
体内	从左到右依次将纯溶剂加入产品，现配现用(数据来自Selleck实验检测而非文献)： 4% DMSO+30% PEG 300+5% Tween 80+ddH2O	5mg/mL

* 溶解度检测是由Selleck技术部门检测的，可能会和文献中提供的溶解度有所差异，这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据 Download Dasatinib SDF

分子量	488.01
化学式	C₂₂H₂₆ClN₇O₂S
CAS号	302962-49-8
储存条件	3 years -20°C powder
储存条件	2 years -80°C in solvent
别名	BMS-354825

计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系，公式为:

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

质量

浓度

体积

分子量
=

×

×

*在配置溶液时，请务必参考Selleck产品标签上、MSDS / COA（可在Selleck的产品页面获得）批次特异的分子量使用本工具。

稀释计算器

用本工具协助配置特定浓度的溶液，使用的计算公式为：

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入输出 )

C1

V1

C2

V2
×

=

×

在配置溶液时，请务必参考Selleck产品标签上、MSDS / COA（可在Selleck的产品页面获得）批次特异的分子量使用本工具。.

连续稀释计算器方程

连续稀释
初始浓度:
稀释倍数:

计算结果

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

分子量计算器

通过输入化合物的化学式来计算其分子量：

注：化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量	浓度	体积	分子量
=	×	×
计算

临床试验信息 (data from https://clinicaltrials.gov, updated on )

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT04063124	Not yet recruiting	Alzheimer Disease	The University of Texas Health Science Center at San Antonio\|Mayo Clinic	December 2019	Phase 1\|Phase 2
NCT04115059	Not yet recruiting	Waldenstrom Macroglobulinemia\|DASATINIB	Jorge J. Castillo MD\|Bristol-Myers Squibb\|Dana-Farber Cancer Institute	November 2019	Phase 1
NCT03318770	Not yet recruiting	Acute Lymphoblastic Leukemia	Gruppo Italiano Malattie EMatologiche dell''Adulto	December 2018	--
NCT03625388	Recruiting	Chronic Myelogenous Leukemia	Hikma Pharmaceuticals LLC	November 5 2018	Phase 2
NCT03193281	Recruiting	Chronic Myeloid Leukemia	University of Auckland New Zealand\|Leukaemia & Blood Cancer New Zealand	July 17 2017	Phase 2
NCT03041701	Recruiting	Rhabdomyosarcoma\|Rhabdomyosarcoma- Alveolar\|Rhabdomyosarcoma-Embryonal	National Cancer Institute (NCI)\|National Institutes of Health Clinical Center (CC)	July 7 2017	Phase 1\|Phase 2

技术支持

在订购、运输、储存和使用我们的产品的任何阶段，您遇到的任何问题，均可以通过拨打我们的热线电话400-668-6834，或者技术支持邮箱tech@selleck.cn，直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题，请给我们留言。

常见问题及建议解决方法

问题 1：
what’s the difference between S1021 and S7782? Which one is better for in vivo studies?
回答：
Usually, hydrate will be more stable and dissolve better than free base. But this compound (S1021) dissolves better in DMSO than hydrate one (S7782).
问题 2：
Can I give dasatinib to mice by oral gavage? If so, how to dissolve the drug?
回答：
Our S1021 Dasatinib in 1% DMSO+30% PEG 300+1% Tween 80 at 30 mg/ml is a suspension which you can administrate to mice via oral gavage. If you want a clear solution, it can be dissolved in 4% DMSO+30% PEG 300+5% Tween 80+ddH2O at 5 mg/ml clearly.

Src Signaling Pathway Map

Src Inhibitors with Unique Features

泛Src抑制剂

Saracatinib (AZD0530) : Pan-Src inhibitor, IC50=2.7-11 nM for c-Src/c-Yes/Fyn/Lyn/Blk/Fgr/Lck.
FDA批准的Src抑制剂

Bosutinib (SKI-606) : Approved by FDA for Ph+ chronic myelogenous leukemia (CML).
最新的Src抑制剂

PP1 : Potent and selective Src inhibitor for Lck/Fyn with IC50 of 5 nM/ 6 nM.
经典的Src抑制剂

KX2-391 : The first clinical Src inhibitor (peptidomimetic class) that targets the peptide substrate site of Src, with GI50 of 9-60 nM in cancer cell lines.

研究领域

产品类型

Dasatinib

客户使用Selleck该产品发表文献137篇：

产品安全说明书

Src抑制剂选择性比较

生物活性

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

参考文献

溶解度 (25°C)

化学数据 Download Dasatinib SDF

计算器

摩尔浓度计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

稀释计算器

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

连续稀释计算器方程

连续稀释

计算结果

分子量计算器

总分子量：g/mol

摩尔浓度计算器

临床试验信息 (data from https://clinicaltrials.gov, updated on )

技术支持

常见问题及建议解决方法

Src Signaling Pathway Map

Src Inhibitors with Unique Features

相关Src产品